These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11349082)

  • 21. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
    Gurunathan S; Prussin C; Sacks DL; Seder RA
    Nat Med; 1998 Dec; 4(12):1409-15. PubMed ID: 9846579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice.
    López-Fuertes L; Pérez-Jiménez E; Vila-Coro AJ; Sack F; Moreno S; Konig SA; Junghans C; Wittig B; Timón M; Esteban M
    Vaccine; 2002 Dec; 21(3-4):247-57. PubMed ID: 12450700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c Mice.
    Stober CB; Lange UG; Roberts MT; Alcami A; Blackwell JM
    Infect Immun; 2007 Feb; 75(2):852-60. PubMed ID: 17101647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant.
    Skeiky YA; Coler RN; Brannon M; Stromberg E; Greeson K; Crane RT; Webb JR; Campos-Neto A; Reed SG
    Vaccine; 2002 Sep; 20(27-28):3292-303. PubMed ID: 12213399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges and perspectives in vaccination against leishmaniasis.
    de Oliveira CI; Nascimento IP; Barral A; Soto M; Barral-Netto M
    Parasitol Int; 2009 Dec; 58(4):319-24. PubMed ID: 19698801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy of murine cutaneous leishmaniasis by DNA vaccination.
    Handman E; Noormohammadi AH; Curtis JM; Baldwin T; Sjölander A
    Vaccine; 2000 Jul; 18(26):3011-7. PubMed ID: 10825604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT; Vale AM; França da Silva JC; da Costa RT; Quetz Jda S; Martins Filho OA; Reis AB; Corrêa Oliveira R; Machado-Coelho GL; Bueno LL; Bethony JM; Frank G; Nascimento E; Genaro O; Mayrink W; Reed S; Campos-Neto A
    Vet Res; 2005; 36(5-6):827-38. PubMed ID: 16120256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen.
    Masina S; M Gicheru M; Demotz SO; Fasel NJ
    J Infect Dis; 2003 Oct; 188(8):1250-7. PubMed ID: 14551897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of IL-22 on DNA vaccine encoding LACK gene of Leishmania major in BALB/c mice.
    Hezarjaribi HZ; Ghaffarifar F; Dalimi A; Sharifi Z; Jorjani O
    Exp Parasitol; 2013 Jul; 134(3):341-8. PubMed ID: 23541883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major.
    Ghaffarifar F; Jorjani O; Sharifi Z; Dalimi A; Hassan ZM; Tabatabaie F; Khoshzaban F; Hezarjaribi HZ
    APMIS; 2013 Apr; 121(4):290-8. PubMed ID: 23030526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection.
    Roberts MT; Stober CB; McKenzie AN; Blackwell JM
    Infect Immun; 2005 Nov; 73(11):7620-8. PubMed ID: 16239566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection.
    Sjölander A; Baldwin TM; Curtis JM; Bengtsson KL; Handman E
    Vaccine; 1998 Dec; 16(20):2077-84. PubMed ID: 9796067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
    Afonso LC; Scharton TM; Vieira LQ; Wysocka M; Trinchieri G; Scott P
    Science; 1994 Jan; 263(5144):235-7. PubMed ID: 7904381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
    Piedrafita D; Xu D; Hunter D; Harrison RA; Liew FY
    J Immunol; 1999 Aug; 163(3):1467-72. PubMed ID: 10415048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T cells that react to the immunodominant Leishmania major LACK antigen prevent early dissemination of the parasite in susceptible BALB/c mice.
    Schilling S; Glaichenhaus N
    Infect Immun; 2001 Feb; 69(2):1212-4. PubMed ID: 11160025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [LACK protein of Leishmania major: a pivotal antigen in the immune relation between host and parasite].
    Gangneux JP
    Sante; 1997; 7(6):425. PubMed ID: 9503502
    [No Abstract]   [Full Text] [Related]  

  • 38. Expression cloning of a protective Leishmania antigen.
    Mougneau E; Altare F; Wakil AE; Zheng S; Coppola T; Wang ZE; Waldmann R; Locksley RM; Glaichenhaus N
    Science; 1995 Apr; 268(5210):563-6. PubMed ID: 7725103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
    Ramírez L; Santos DM; Souza AP; Coelho EA; Barral A; Alonso C; Escutia MR; Bonay P; de Oliveira CI; Soto M
    Vaccine; 2013 Feb; 31(9):1312-9. PubMed ID: 23313653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice.
    Gomes DC; Pinto EF; de Melo LD; Lima WP; Larraga V; Lopes UG; Rossi-Bergmann B
    Vaccine; 2007 Mar; 25(12):2168-72. PubMed ID: 17240003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.